Elevated IGF-1 levels are associated with increased cancer risk in observational studies, particularly for hormone-sensitive tumors. Pollak, Nature Reviews Cancer Avoid use if you have: Personal or family history of cancer Undiagnosed growths or polyps A genetic predisposition to hormone-related cancers Diabetics and Individuals with Insulin Resistance IGF-1 directly affects glucose uptake and insulin signaling
Vaginal Dryness Vaginal dryness is a common symptom of menopause, caused by decreased hormone production leading to thinner, drier, and less elastic vaginal tissues
Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.[2][3] It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.[4] Ipamorelin significantly increases plasma growth hormone (GH).[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH.[3] Ipamorelin Peptide is under active investigation in a number of cell culture and animal models
As we age or undergo environmental stress, natural glutathione levels may decline
A stapled -helical peptide target to EFHD2 has been shown have effect on protecting MASH in mice
